论文部分内容阅读
目的:探讨布地奈德联合万托林雾化吸入治疗小儿支气管哮喘的临床疗效和安全性。方法:70例支气管哮喘患儿随机分为治疗组和对照组。对照组给予常规治疗,治疗组在常规治疗的基础上,给予布地奈德联合万托林雾化吸入治疗,连续治疗3天。观察治疗前后两组主要临床症状和体征改善情况,评价临床疗效,观察不良反应。结果:治疗组临床疗效总有效率为94.3%,显著高于对照组(71.4%),相比较有统计学差异(χ2=6.437,P<0.05)。治疗组喘憋消失、咳嗽缓解、肺部湿啰音和肺部哮鸣音消失时间明显低于对照组,两组相比较有统计学差异(t=5.898、4.899、4.982、7.420,P<0.01)。两组均无不良反应发生。结论:布地奈德联合万托林雾化吸入治疗小儿支气管哮喘是一种安全、有效的治疗方法,临床值得推广应用。
Objective: To investigate the clinical efficacy and safety of budesonide combined with vomotolin inhalation for bronchial asthma in children. Methods: Seventy children with bronchial asthma were randomly divided into treatment group and control group. The control group was given routine treatment. The treatment group was treated with inhalation of budesonide combined with wanolin for 3 days on the basis of routine treatment. Before and after treatment to observe the main clinical symptoms and signs of improvement, evaluate the clinical efficacy, adverse reactions observed. Results: The total effective rate of the treatment group was 94.3%, which was significantly higher than that of the control group (71.4%) (χ2 = 6.437, P <0.05). The disappearance of wheezing, relieving cough, the disappearance of lung wet rales and pulmonary wheeze in the treatment group were significantly lower than those in the control group (t = 5.898, 4.899, 4.982, 7.420, P <0.01) ). No adverse reactions occurred in both groups. Conclusion: The combination of budesonide and vaterolin inhalation for bronchial asthma in children is a safe and effective treatment, which is worth popularizing and clinical application.